Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could boost colorectal cancer screening rates

NCT ID NCT05987709

Diagnosis Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether offering a simple blood test (GuardantSHIELD) could help more people complete colorectal cancer screening compared to usual care. Over 2,000 adults aged 45-75 who were overdue for screening took part. The main goal was to see if more people got screened within 3 months when offered the blood test.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GuardantSHIELD Blood Test
What this could lead to
If successful, this blood test could offer a simpler, less invasive option to encourage more people to get screened for colorectal cancer.
What could go wrong
This is a completed study comparing screening completion rates, not a treatment trial. The blood test may not detect all cancers and abnormal results still require a follow-up colonoscopy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,004 people

The number who actually took part.

Started

Mar 2022

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 45-75 * Received a FIT test in the last 3-9 months yet did not return their FIT * Upcoming appointment or willing to reschedule an appointment at KPNW within 2 - 6 weeks * Able and willing to provide informed consent if in the intervention arm Exclusion Criteria: * On KPNW's do not contact list * Having a legal authorized representative * Non-English speakers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer

Contacts and locations

Locations

  • Kaiser Permanente Northwest

    Portland, Oregon, 97227, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.